Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Business Update | Fri 11, 2023
Miamind® Neurostimulator officially registered with Swissmedic and MHRA
Excellent news for patients. After three years of development, Miamind®, the patient-specific neurostimulator for non-invasive brain stimulation, can
Events & Conferences | Mon 11, 2023
Bottneuro at MEDICA 2023
Bottneuro is attending the this years MEDICA conference in Düsseldorf, Germany, one of the largest medical B2B trade fairs globally!
Events & Conferences | Mon 10, 2023
Bottneuro at the Biosensors for Medical Wearables Conference
The Biosensors for Medical Wearables Conference is back in Boston!
Events & Conferences | Mon 10, 2023
Bottneuro at the UK Medtech Mission for Swiss Start-ups
The UK Medtech Mission for Swiss Start-ups is set to kick off, and Bottneuro is thrilled to have been selected to be a part of this exciting week!
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
